Literature DB >> 17321683

Complex movement behaviour and progression of Huntington's disease.

Jürgen Andrich1, Carsten Saft, Natalie Ostholt, Thomas Müller.   

Abstract

Instrumental measurement of complex motion sequences with a peg insertion paradigm reflects impairment in patients with Huntington's disease (HD). Objectives were to study progress of HD symptoms and peg insertion results in 39 HD patients without symptomatic drug treatment over an interval of 3 years. Assessments were at baseline and 3 years later. Unified Huntington's Disease Rating Scale (UHDRS) total score, computed arm score and the specific rating outcomes for bradykinesia, chorea, dystonia and oculomotor symptoms significantly increased over a 3-year period. Motor test outcomes significantly worsened. Cognitive scores did not change significantly, but were significantly related to the peg insertion outcomes and to the various UHDRS rating results at both assessments. Peg insertion scores are nonspecific diagnostic marker for progress in HD. Peg insertion particularly reflects motor impairment and additionally higher cognitive and executive dysfunction. These higher cognitive functions are associated with frontostriatal pathology in HD. Our study results suggest that our motor test reflects these emerging deficits of higher cognitive and motor function abilities in HD. We conclude, that instrumental assessment of complex movement sequences is an additional simple method to follow impairment in HD patients in addition to clinical rating.

Entities:  

Mesh:

Year:  2007        PMID: 17321683     DOI: 10.1016/j.neulet.2007.02.027

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  12 in total

Review 1.  Progress and prospects for genetic modification of nonhuman primate models in biomedical research.

Authors:  Anthony W S Chan
Journal:  ILAR J       Date:  2013

Review 2.  Huntington's disease: the coming of age.

Authors:  Mritunjay Pandey; Usha Rajamma
Journal:  J Genet       Date:  2018-07       Impact factor: 1.166

Review 3.  Exploring the Potential of Small Molecule-Based Therapeutic Approaches for Targeting Trinucleotide Repeat Disorders.

Authors:  Arun Kumar Verma; Eshan Khan; Sonali R Bhagwat; Amit Kumar
Journal:  Mol Neurobiol       Date:  2019-08-09       Impact factor: 5.590

4.  The relationship between impairment of voluntary movements and cognitive impairment in Huntington's disease.

Authors:  Jirí Klempír; Olga Klempírová; Jan Stochl; Natasa Spacková; Jan Roth
Journal:  J Neurol       Date:  2009-05-16       Impact factor: 4.849

Review 5.  Treatment of Huntington's disease.

Authors:  Samuel Frank
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 6.  Advances in the pharmacological management of Huntington's disease.

Authors:  Samuel Frank; Joseph Jankovic
Journal:  Drugs       Date:  2010-03-26       Impact factor: 9.546

7.  Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease.

Authors:  Samuel Frank
Journal:  Neuropsychiatr Dis Treat       Date:  2010-10-05       Impact factor: 2.570

8.  Music perception and movement deterioration in Huntington's disease.

Authors:  Christian Beste; Anne Schüttke; Bettina Pfleiderer; Carsten Saft
Journal:  PLoS Curr       Date:  2011-09-20

9.  No evidence of impaired gastric emptying in early Huntington's Disease.

Authors:  Carsten Saft; Jürgen Andrich; Marc Fälker; Sarah Gauda; Sina Küchler; Dirk Woitalla; Oliver Goetze
Journal:  PLoS Curr       Date:  2011-10-25

10.  Novel Nut and Bolt Task Quantifies Motor Deficits in Premanifest and Manifest Huntington's Disease.

Authors:  Lucy M Collins; Faye Begeti; Francesca Panin; Alpar S Lazar; Travis Cruickshank; Mel Ziman; Sarah L Mason; Roger A Barker
Journal:  PLoS Curr       Date:  2015-09-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.